Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosa-trienoic acid levels
CA 2092722 A1 · Owner: Levere, Richard D. · Inventors: Dunn, Michael W.; Schwartzman, Michal L.; Levere, Richard D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method for treating or preventing ocular swelling and corneal-conjunctival inflammation. This is accomplished by administering to the eye of a subject either before or, after exposure to an ocular swelling stimulus an amount of a, heme oxygenase inducing agent sufficient to increase levels of heme oxygenase in the eye and thereby to reduce or to regulate the amount of 19 and 20 hydroxyeicosatetraenoic and 12(R)DiHETE acids present. Particularly preferred agents include stannous compounds such as SnCl2, other metals, heme derivatives and Vitamin B12. These compounds may be administered in various forms.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 10, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.